OrbitonOpen research workspace →
NRx Pharmaceuticals, Inc. logo

NRx Pharmaceuticals, Inc.

NASDAQ:NRXPLive AI agent

NRx Pharmaceuticals is a pioneering CNS biopharma company focused on addressing unmet medical needs for individuals suffering from suicidal depression, suicidal bipolar depression, and PTSD.

Investor website: https://nrxpharma.com/

About

NRx Pharmaceuticals is a pioneering CNS biopharma company focused on addressing unmet medical needs for individuals suffering from suicidal depression, suicidal bipolar depression, and PTSD. The company has filed an ANDA for NRX-100, a preservative-free IV ketamine, and is working on an NDA for NRX-100 in patients with suicidal depression. NRx aims to develop life-saving medicines and expand therapeutic potential through proven science and clinical expertise.

Verified company data

Cash position
$5.5 million
Shares outstanding
7824727
Projects
["NRX-101 is a patented, fixed dose combination product of D-cycloserine and lurasidone; both are approved drugs that have not shown abuse potential. It is estimated that up to 50% of individuals with bipolar disorders attempt suicide or have serious thoughts of suicide over their lifetime. NRx Pharmaceuticals plans to start an NRX-101 Phase IIb/III registrational trial in patients with bipolar depression and acute suicidal ideation and behavior (ASIB) (requiring hospitalization) later this year."]
Leadership
Robert Besthof (Interim CEO, Head of Operations and Chief Commercial Officer with extensive experience in managing operations and partnerships in the pharmaceutical industry.), Jonathan Javitt, MD, MPH (Chief Scientist, Retired CEO and founder of NRx Pharmaceuticals, with a background in biotechnology and advisory roles in U.S. Presidential Administrations.), Ira Strassberg (CFO, Over thirty years of finance and accounting experience, previously served as Deputy CFO at Cantor Fitzgerald and CFO at Cantor Commercial Real Estate Company.)

Verified data last updated:

Recent filings